1. Pink Sheet

Gilead's Compassionate Use Data Promising, But Imminent COVID-19 Treatment Shift Unlikely

 
• By Sarah Karlin-Smith

Interpretation of remdesivir's compassionate use data is complicated by typical disease course of COVID-19 patients. The uncontrolled data raises hopes for positive trials but is unlikely to change current treatment protocols.

Gilead sign at headquarters in Silicon Valley. Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs - Foster City, California, USA - 2020
Gilead's experimental antiviral remdesivir may have helped COVID-19 patients, compassionate use data shows • Source: Shutterstock

Promising data on Gilead Sciences Inc.’s experimental antiviral remdesivir given as compassionate use to more than 50 hospitalized COVID-19 patients is unlikely to change current clinical trials or clinical care.

That’s largely due to the limitations of the uncontrolled data in a disease where most patients will improve over time, along with the rapid conclusion expected of already ongoing studies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D